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Urinary 8-hydroxy-2’-deoxyguanosine (8-OHdG) is a widely used noninvasive 
biomarker of oxidative stress. A selective, sensitive and rapid method for determining 
8-OHdG in human urine was developed using hydrophilic interaction chromatography- 
tandem mass spectrometry (HILIC-MS/MS) with electrospray ionization. 8-OHdG and 
isotopically labeled 8-OHdG (internal standard) were separated on a HILIC column 
with a mobile phase of 10 mM ammonium acetate : acetonitrile (1 : 9, v/v) within 10 
min and detected by using a positive electrospray ionization interface under the selected 
reaction monitoring mode. The detection limits of 8-OHdG (corresponding to a 
signal-to-noise ratio of 3) for the HILIC-MS/MS system and the conventional method 
using a reversed-phase column with MS/MS were 1.0 and 26.0 fmol/injection, 
respectively. The proposed method makes it possible to monitor the basal level of 
urinary 8-OHdG from non-exposed healthy subjects and can be used for large-scale 
human studies. 
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Oxidative stress in an organism arises from excessive generation of reactive oxygen 
species (ROS) such as superoxide radicals, hydrogen peroxide and hydroxyl radicals or 
from depletion of antioxidants [1]. The production of ROS can be induced by both 
endogenous and exogenous factors [2]. While endogenous factors include physiological 
processes, exogenous factors include environmental sources such as smoking, diet and 
pollution [3]. ROS may cause oxidative damage to nucleic acids, proteins, and lipids [2]. 
In particular, oxidative damage to DNA has been associated with numerous pathological 
conditions, having both genetic and epigenetic consequences [4-6]. To understand how 
ROS affect normal and pathological processes, an indicator to assess oxidative stress in 
vivo is required. 
The oxidized product of DNA, 8-hydroxy-2’-deoxyguanosine (8-OHdG), is the most 
frequently measured biomarker of the oxidative stress [7, 8]. The 8-OHdG has been 
analyzed in various kinds of samples, such as urine, serum, peripheral blood leukocyte, 
and organ tissue [9]. Measurements of 8-OHdG in urine samples are especially 
well-suited to large-scale human studies and clinical applications because they are 
noninvasive [10, 11]. Urinary 8-OHdG has been analyzed by several methods, such as 
enzyme-linked immunosorbent assay (ELISA) [12, 13], high-performance liquid 
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chromatography with electrochemical detection (HPLC-ECD) [14], gas chromatography 
with mass spectrometry (GC/MS) [15, 16], and liquid chromatography with tandem 
mass spectrometry (LC/MS/MS) [17-26]. The ELISA method suffers from the problem 
of non-selectivity because the antibody may cross-react with other substances present in 
urine [12, 27, 28]. HPLC-ECD has often been used [29], but it suffers from possible 
interference from the biological matrix, incompatibility of a stable isotope labeled 
internal standard [16, 21]. For GC/MS analysis, 8-OHdG must be purified by HPLC and 
derivatized before analysis [15, 16, 28]. 
LC-MS/MS has been increasingly applied to detect urinary 8-OHdG. LC-MS/MS, 
when combined with the isotope dilution technique, is highly selective, sensitive, and 
accurate, and does not require derivatization [28]. In most of previous LC-MS/MS 
studies, reversed-phase columns have been used to separate 8-OHdG [17-26]. As a polar 
compound, 8-OHdG is hardly retained on a reversed-phase column, even though 
aqueous mobile phases are used. Such poor retention of 8-OHdG and its insufficient 
separation from polar components in the matrix may lead to matrix effects, which can 
increase or decrease the 8-OHdG MS signal [30]. In addition, aqueous mobile phases 
that are used to retain polar compounds on reversed-phase columns are not suited for 
electrospray ionization (ESI) conditions [30]. Indeed, urinary 8-OHdG levels have even 
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been below the detection limit of LC-MS/MS method (7.5 fmol/injection, S/N= 3) [27, 
31]. Therefore, a more sensitive LC-MS/MS method is required to measure basal levels 
of urinary 8-OHdG in non-exposed healthy subjects. 
In recent years, hydrophilic interaction chromatography (HILIC) has been 
increasingly used in LC-MS/MS for analyzing polar compounds such as metabolites in 
biological samples. Under HILIC conditions, the analyte interacts with a hydrophilic 
stationary phase and is eluted with a high concentration of organic solvent (typically 
acetonitrile with a small percentage of water/buffer). The highly organic mobile phase 
can result in increased sensitivity with ESI-MS detection [30, 32]. 
In this study, we developed an improved LC-MS/MS method for measuring urinary 
8-OHdG using a HILIC column. We found that the HILIC column provided much 





The 8-OHdG and [15N5]8-OHdG were purchased from Sigma (MO, USA) and 
Cambridge Isotope Laboratories (MA, USA), respectively. HPLC grade acetonitrile was 
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obtained from Kanto Chemical (Tokyo, Japan), and water from a Milli-Q water 
purification system (Millipore, Bedford, MA, USA). All other chemicals and solvents 
used were of an analytical grade. 
 
2.2. Samples preparation 
Urinary samples were pretreated as described previously with a slight modification 
[22, 28]. After centrifugation at 2150×g for 10 min, a 100 L aliquot of each 
supernatant was diluted with 900 L of water and spiked with 10 pmol of the stable 
isotope labeled internal standard (IS), [15N5]8-OHdG. The diluted sample was subjected 
to solid-phase extraction using Oasis HLB cartridge (3 cc, 60 mg; Waters, Milford, MA, 
USA) that had been primed with 1 mL of methanol and 1 mL of water. After sample 
loading, the cartridge was sequentially washed with 1 mL of water. The 8-OHdG was 
eluted from the cartridge with 500 L of water : acetonitrile (1 : 1, v/v), and evaporated 
to dryness using a centrifugal vacuum evaporator. The residue was redissolved in 100 
L of water : acetonitrile (1 : 9, v/v), and an aliquot of 20 L was injected into the LC–
MS/MS system. 
 
2.3. 8-OHdG analysis by HILIC-MS/MS 
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2.3.1. Apparatus and chromatographic conditions 
The Agilent 1100 series LC system consists of a G1379A degasser, a G1312A binary 
pump, a G1367A autosampler, and a G1316A column oven (all from Agilent 
Technologies, Palo Alto, CA, USA). The chromatographic separation of 8-OHdG in the 
pretreated urine samples was performed on a COSMOSIL HILIC (150 mm×2.0 mm i.d., 
5 m, Nacalai Tesque, Kyoto, Japan), kept at the temperature of 40˚C. The column was 
eluted isocratically with 10 mM ammonium acetate : acetonitrile (1 : 9, v/v) at a flow 
rate of 0.4 mL/min. The retention time of the analyte was optimized by varying the 
mobile phase acetonitrile content between 70% and 95% with 10 mM ammonium 
acetate and by varying the aqueous buffer concentration between 10 and 50 mM with 
90% acetonitrile. The retention factor (k) of 8-OHdG was defined as k = (tR – t0)/t0, 
where tR and t0 are the retention times of the analyte and the hold-up time, respectively. 
Sample volumes of 20 L were injected for each analysis. The mass spectrometric 
analyses were performed using an API 4000 Q-Trap tandem mass spectrometer 
(Applied Biosystems, CA, USA) equipped with an electrospray ionization (ESI) and 
operated in a positive ion mode. Sensitivity of the selective reaction monitoring (SRM) 
was optimized by testing with an infusion of 8-OHdG under the mobile phase condition. 
The mass spectrometer was operated under SRM mode of the transitions at m/z 284.3→
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167.9 for 8-OHdG and at m/z 289.1→173.0 for [15N5]8-OHdG (IS) with dwell times of 
1000 ms. The spray voltage was maintained at 5.5 kV. Nitrogen gas was used as the 
collision gas (4 psi) and curtain gas (20 psi), whereas zero grade air was used as the 
nebulizer gas (40 psi) and heated gas (60 psi). Source temperature was set at 600˚C. The 
collision energy and declustering potential were set at 19 V and 71 V, respectively. 
Analyst software (version 1.4, Applied Biosystems) was used to control the LC–MS/MS 
system, and to acquire and process the data. 
 
2.3.2 Calibration curve and validation 
Calibration curves for quality control (QC) samples were obtained from the ratio of 
peak areas of 8-OHdG and [15N5]8-OHdG (IS) using 0.1 mL human urine samples from 
six humans spiked with 8-OHdG at final concentrations of 0.2, 5, 10, 30, 50, 100 
nmol/L. Standard curves were also obtained from plotting the peak area ratio against the 
same six concentrations of the analyte as the spiked urine samples (n = 6 for each). The 
lower limit of quantification (LLOQ) was determined as the lowest standard on the 
calibration curve that gave a signal-to-noise ratio of more than ten and reached a 
precision of 20% and an accuracy of 80-120%. The limit of detection (LOD) was 
determined as the lowest concentration that gave a signal-to-noise ratio of more than 
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three. To evaluate the intra- and inter-day accuracy and precision, the stock solution of 
8-OHdG was added to urine at concentrations of 10 and 50 nmol/L in 0.1 mL urine. The 
spiked samples, together with non-spiked samples, were analyzed using HILIC-MS/MS 
and 8-OHdG concentrations were calculated using a standard curve. Accuracy was 
expressed as the ratio of the quantified concentration to the known concentration of 
8-OHdG. To evaluate the intra-day precision, the non-spiked samples and the samples 
spiked at the two levels were prepared five times per day. The inter-day precision was 
determined using five independent experiments. The precision was calculated as the 
relative standard deviation (RSD) (%) of the replicates. 
 
2.4. 8-OHdG analysis by LC-MS/MS using reversed-phase column 
On the basis of previously reported LC-MS/MS method [25], chromatographic 
separation of 8-OHdG and [15N5]8-OHdG (IS) in urine samples was performed on a 
XBridge C18 column (150mm×2.1mm i.d., 3.5 m, Waters) with a guard column 
(XBridge C18 column, 10 mm×10 mm i.d., 5 m, Waters). The elution was run 
isocratically with a mobile phase consisting of 10 mM ammonium acetate : methanol 
(19 : 1, v/v) at a flow rate of 0.4 mL/min. The column temperature was set at 40˚C. The 





3. Results and discussion 
3.1. Mass spectrometry and chromatography 
The full scan mass spectrum of 8-OHdG in the positive ESI mode and the 
fragmentation pattern of protonated molecular ion [M+H]+ observed in this study were 
consistent with those of previous studies [17, 18, 24, 26]. The transition from the 
molecular ion [M+H]+ to the most intense fragment was recorded in the selective 
reaction monitoring (SRM) acquisition mode. The main product ions of 8-OHdG and 
[15N5]8-OHdG (IS) were m/z 167.9 and 173.0 [M+H−116]+, respectively. Therefore, the 
[M+H]+ →[M+H−116]+ transition was used in the SRM mode.  
We examined the effect of the acetonitrile concentration in the mobile phase of the 
HILIC column on the retention time of the analytes. The column was operated under 
isocratic elution conditions using acetonitrile concentration between 70 to 95%, at the 
interval of 5%. The retention factor (k) increased with the increasing acetonitrile 
concentration (Fig. 1). The high content of acetonitrile increases the hydrophilic 
interactions between the analytes and the stationary phase [33]. At 95% acetonitrile, 
8-OHdG was retained for over 15 min on the column and its peak shape was broad. The 
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retention time of charged analytes can be affected by adding salt to the mobile phase 
due to the electrostatic interactions between the column and analytes [33, 34]. For a salt, 
we selected ammonium acetate because of its solubility in concentrated acetonitrile 
solutions, and its volatility at the ion source. The effect of the buffer concentration in the 
mobile phase on the retention of the analyte was investigated in the range 10-50 mM. 
Increasing the buffer concentration only slightly decreased the retention and did not 
influence the peak shape (data not shown). Finally, the analytes were separated by 
isocratic elution with 10 mM ammonium acetate : acetonitrile (1 : 9, v/v). The analyte 
and the internal standard eluted within 10 min using the optimized mobile phase (Fig. 2, 
A-1 and A-2). 
 
3.2. Calibration curve and validation 
The calibration curve for the standard compound was linear (r2 > 0.999) for 
concentrations in the range of 0.2–100 nmol/L (LLOQ: 0.2 nmol/L), which covers the 
lower range of the reported levels of 8-OHdG in human urine [29], and the slope was 
0.00630±0.00026 (mean±S.D. RSD, 4.1%).  
Representative SRM chromatograms for the analyte and the internal standard of a 
urine sample from a non-smoker showed that the physiological components of the urine 
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did not interfere with the identification and quantification of the analytes in the 
chromatograms (Fig. 2, B-1 and B-2). The matrix effect on the mass spectrometric 
response was evaluated by comparing the slope of the calibration curve with the slope 
obtained in the presence of urine matrix. Six curves were obtained using six different 
urine samples, each spiked with six different amounts of 8-OHdG. The mean slope was 
0.00655±0.00043 (mean±S.D., RSD, 6.6%), which was almost identical to the mean 
slope obtained with the standard solutions. This clearly showed that the matrix did not 
affect the calibration curve. Therefore, 8-OHdG was quantified by using the calibration 
curve obtained from the standard solution. 
The precision and accuracy of 8-OHdG determination in human urine with the 
HILIC–MS/MS system were examined by adding two different known amounts of 
8-OHdG to a urine sample. The RSDs of the intra-day precision assay (n = 5) were in 
the range 2.3–2.6%, and those of the inter-day assay (n = 5) were in the range 2.1–4.0% 
(Table 1). The accuracy values (%) of the intra-day study and the inter-day assay were 
in the range 96–102%. Both intra- and inter-day precision and accuracy values were 
satisfactory for determining 8-OHdG in human urine. 
 
3.3. Comparison of the HILIC column with a reversed-phase column 
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The instrumental detection limit of 8-OHdG measured by the HILIC-MS/MS was 1.0 
fmol/injection (signal-to-noise ratio, S/N >3). In contrast, the detection limit achieved 
with a reversed-phase column and the same detection system was 26.0 fmol/injection 
under optimal instrumental conditions. Our detection limit of 1.0 fmol was considerably 
lower than the detection limits reported for other previous LC-MS/MS methods: 20 
fmol [17], 7 fmol (S/N=3) [18], 5 fmol (S/N=4) [19] and 7.5 fmol/injection (S/N=3) [27, 
31]. The low detection limit of method enables the measurement of basal levels of 
urinary 8-OHdG in non-exposed healthy subjects that were not quantified in the 
previous report [27, 31]. Furthermore, the analysis can be completed in 10 min and 




HILIC-MS/MS provides a selective, sensitive and rapid method for determining 
8-OHdG in human urine. The method has acceptable linearity, accuracy, and precision, 
and is more sensitive than previously described LC-MS/MS methods that have been 
used in reversed-phase columns. The proposed HILIC–MS/MS method is well suited 
for large-scale human studies and clinical studies, and would also be applicable to 
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analysis of 8-OHdG in not only urine but also other biological fluids such as plasma, 
serum and saliva, and in tissue. 
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Fig. 1 Effect of acetonitrile content in the mobile phase on the retention of 8-OHdG. 
 
Fig.2 Representative SRM chromatograms (transition: m/z 284.3→167.9 for 8-OHdG 
and m/z 289.1→173.0 for the internal standard ([15N5]8-OHdG)) of a standard solution 
corresponding to 200 fmol 8-OHdG/injection (A) and a non-smoker urine sample (B) 
(A-1 and B-1 panels for 8-OHdG; A-2 and B-2 panels for the internal standard). 
 
Intra-day assay (n = 5) Inter-day assay (n = 5)
Added amounts
(pmol/mL urine) 0 10 50 0 10 50
Found ± SD
(pmol/mL urine) 17.5± 0.4 27.0 ± 0.7 68.5 ± 1.6 16.8 ± 0.4 26.9 ± 0.7 67.5 ± 2.7
RSD (%) 2.3 2.6 2.4 2.1 2.8 4.0
Accuracy (%) - 96 102 - 101 101
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